📰 GPCR Weekly News, August 7 to 13, 2023

Hello GPCR enthusiasts! Check out the latest advancements in GPCR studies.

Save the date! On September 22nd, we're hosting the Dr. GPCR Symposium on 'GPCRs as Therapeutic Modalities'. Want to share your project in a casual way? Submit a 1-minute abstract video using this form! We'll be having a discussion session on Kumospace, which is replacing the poster session. The GPCR Retreat is just around the corner! As proud sponsors, we invite you to join us. Submit your abstracts for poster presentation using this form - short talks will be selected from these submissions. Remember, the early-bird registration and Abstract submission deadline is September 8, and the final registration deadline is September 21. We're looking forward to seeing you there!

Make sure to stay in the loop with the Dr. GPCR Newsletter!

And, don't forget to catch up on the latest Classified GPCR News from August 7 to 13, 2023.

GPCR Activation and Signaling

• Tail engagement of arrestin at the glucagon receptor

• Gα protein signaling bias at 5-HT1A receptor

GPCRs in Cardiology, Endocrinology, and Taste

• Gβγ-SNAP25 exocytotic brake removal enhances insulin action, promotes adipocyte browning, and protects against diet-induced obesity

GPCRs in Neuroscience

• The neuropeptide receptor npr-38 regulates avoidance and stress-induced sleep in Caenorhabditis elegans

• Towards the convergent therapeutic potential of GPCRs in autism spectrum disorders

GPCRs in Oncology and Immunology

• Molecular characterization of breast cancer cell pools with normal or reduced ability to respond to progesterone: a study based on RNA-seq

Reviews, GPCRs, and more

• Tri-part NanoLuc as a new split technology with potential applications in chemical biology: a mini-review

• YAP/TAZ: Molecular pathway and disease therapy

• Primary cilia in skeletal development and disease

Industry News

• Addex Reports 2023 Half Year And Second Quarter Financial Results And Provides Corporate Update

• Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732

• Exscientia Business Update for Second Quarter and First Half of 2023

• Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases

• X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program

• Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights

GPCR Events, Meetings, and Webinars

• ONCORNET2.0 Final Symposium (August 31 - September 1, 2023)

• 3rd Transatlantic ECI GPCR Symposium (September 7 - 8, 2023)

• Discovery On Target - DOT (September 25 - 28, 2023)

• Training Seminar "The Renaissance in GPCRs as Drug Targets: Allosteric Function and Biased Signaling" at the DOT (September 27 - 28, 2023)

• 3rd Annual Meeting IRN I-GPCRNet (October 25 - 27, 2023)

• GPCR Retreat (November 2 - 4, 2023)

• MPGPCR Conference (November 15 -17, 2023)

• ASCEPT Annual Scientific Meeting (November 20 -23, 2023)

• Structure, Mechanism, and Drug Interactions of GPCRs, Ion Channels, and Transport Proteins (March 24 - 29, 2024)

GPCR Jobs

• NEW Postdoctoral Fellow

• NEW Research Laboratory Specialist Associate

• NEW Postdoc Research Associate

• Director, Regulatory Affairs

• Research Scientist/Senior Scientist I - Molecular Pharmacology

• Director, Clinical Data Management

• Director, Discovery Toxicology

• Postdoc Fellow - Dr. Robert Lefkowitz Lab

• Postdoc Fellow - Dr. Robert Lefkowitz Lab

Explore Dr. GPCR Ecosystem